Omeros, Abbott Laboratories, and Eli Lilly and Company are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and market prescription drugs and therapies. For investors, they provide exposure to demand for healthcare and potential for strong growth, but carry specific risks such as clinical trial failures, regulatory approvals, patent expirations, and sector volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Omeros (OMER)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Read Our Latest Research Report on ABT
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read Our Latest Research Report on LLY
Featured Articles
- MarketBeat’s Top Five Stocks to Own in October 2025
- 3 More Hot Tech Stocks With Bullish Charts and Ample Upside
- Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off
- Walmart’s AI Play: OpenAI Deal Forges a New Path to Profitability
- 3 Utilities Plays You Can Lean on During Volatility
- Domino’s Delivers a Q3 Beat—and a Recipe for a Rebound